Paediatrics Search
Paediatrics Paediatrics
otitis%20media%20-%20acute%20(pediatric)
OTITIS MEDIA - ACUTE (PEDIATRIC)
Otitis media is a general term used to describe inflammation of the middle ear which may be caused by an acute infection.
The symptoms are usually nonspecific and include otalgia (pulling of ear in an infant), irritability, otorrhea with or without fever.
Symptoms of upper respiratory tract infection may also be present

Patient Education

  • Advise parent/caregiver on preventable risk factors
  • Pain must be addressed regardless of the need for antibacterial agents, especially in the first 24 hours of illness
  • Review the risks (eg side effects, antibiotic resistance in the community)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Oseltamivir cuts recovery time for flu in real world
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Concomitant PAH may up mortality risk in systemic sclerosis
Roshini Claire Anthony, Yesterday

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

Personalizing treatment for chronic angina with concomitant diseases
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Brodalumab sustains long-term safety, efficacy in psoriatic patients
Stephen Padilla, 4 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.